A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body.

NCT ID: NCT06497088

Last Updated: 2024-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-01

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, efficacy and accuracy of the Nasotrak System in an adult patient population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasogastric Tube Placement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nasotrak System

Group Type EXPERIMENTAL

Nasotrak System

Intervention Type DEVICE

Device: The Nasotrak System

The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.

The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasotrak System

Device: The Nasotrak System

The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.

The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults greater than 18 years of age
* Able to provide informed consent or have a legally authorized representative available to provide informed consent in English
* Clinically requiring a 12 Fr NG/OG tube with X-ray confirmation per standard protocol

Exclusion Criteria

* Female subjects of childbearing age with known pregnancy or lactating.
* Prisoners.
* Unable to consent in English.
* Subjects/ volunteers with pacemakers or life-sustaining devices in the body such as ICD.
* Subjects with a history of:
* Esophageal varices or ulcers.
* Upper airway obstruction.
* Upper GI stenosis or obstruction.
* Trauma involving sinuses, nares face or neck that would prevent nasogastric (NG) or oral tube insertion.
* Deformities of the sinus cavities and/or skull base.
* Esophageal cancer or neoplasm.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nasotrak Medical Pte Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Tan, Beng

Role: STUDY_CHAIR

Nasotrak Medical Pte Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Parkview Regional Medical Center

Fort Wayne, Indiana, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David Tan

Role: CONTACT

+65 6461 7016

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jan Powers, PhD

Role: primary

(260) 266-7761

Jan Powers, PhD

Role: backup

Amanda Alonso

Role: primary

212-342-0261

Michael Owen-Michaane, MD, MA, CNSC

Role: backup

David S. Seres, MD, ScM, PNS, FASPEN

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NST-DHF-076

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phrenic Identification in the ICU
NCT05875883 ACTIVE_NOT_RECRUITING